We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Erythropoietin in Glaucoma: From Mechanism to Therapy.
- Authors
Lai, Yi-Fen; Lin, Ting-Yi; Chen, Yi-Hao; Lu, Da-Wen
- Abstract
Glaucoma can cause irreversible vision loss and is the second leading cause of blindness worldwide. The disease mechanism is complex and various factors have been implicated in its pathogenesis, including ischemia, excessive oxidative stress, neurotropic factor deprivation, and neuron excitotoxicity. Erythropoietin (EPO) is a hormone that induces erythropoiesis in response to hypoxia. However, studies have shown that EPO also has neuroprotective effects and may be useful for rescuing apoptotic retinal ganglion cells in glaucoma. This article explores the relationship between EPO and glaucoma and summarizes preclinical experiments that have used EPO to treat glaucoma, with an aim to provide a different perspective from the current view that glaucoma is incurable.
- Subjects
ERYTHROPOIETIN receptors; RETINAL ganglion cells; ERYTHROPOIETIN; GLAUCOMA; VISION disorders
- Publication
International Journal of Molecular Sciences, 2023, Vol 24, Issue 3, p2985
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms24032985